The ability of various ,-lactamase inhibitors to induce class I I8-lactamases was assessed. Clavulanate was the most active compound, inducing MorganeUa morganii, Aeromonas caviae, and Enterobacter aerogenes over a broad concentration range and Citrobacterfreundii, Pseudomonas aeruginosa, and Serratia marcescens at high concentrations. Disk approximation tests paralleled these results, with clavulanate, but not sulbactam or tazobactam, antagonizing the activity of several j3-lactams against these organisms.
It is now well established that particular P-lactam antibiotics (e.g., cefoxitin) are potent inducers of class I 3-lactamases found in members of the family Enterobacteriaceae and in Pseudomonas aeruginosa. While such induction is reversible, occurring only during exposure to the inducing drug, it is sufficient to impart resistance to ,-lactams in both in vitro and in vivo settings (9) . The P-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) are potentially important adjuvants to ,B-lactam chemotherapy. Each is a strong inhibitor of plasmid-mediated ,B-lactamases among gram-negative organisms, but the three drugs have little antibacterial activity and are not significant inhibitors of chromosomal ,B-lactamases (3, 7) . However, these compounds as P-lactams represent new potential inducers of class I enzymes. Therefore, this study was designed to assess the ability of these P-lactamase inhibitors to induce chromosomal P-lactamases of Aeromonas caviae, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Morganella morganii, P. aeruginosa, and Serratia marcescens.
The inducer potencies of clavulanate, sulbactam, tazobactam, and their companion P-lactam antibiotics (ticarcillin, cefoperazone, and piperacillin, respectively) were quantitatively determined in induction assays with a single wild-type strain of each species. All strains used throughout this study were clinically isolated wild-type organisms susceptible to cefoperazone, piperacillin, and ticarcillin. Cefoxitin, a known potent inducer (11, 12) , was included in all experiments for comparison. Powders of each study compound were obtained as follows: cefoxitin, Merck Sharp & Dohme, Rahway, N.J.; ticarcillin and clavulanate, Beecham Laboratories, Bristol, Tenn.; cefoperazone and sulbactam, Pfizer Pharmaceuticals, New York, N.Y.; and piperacillin and tazobactam, Lederle Laboratories, Pearl River, N.Y. Agar dilution MICs were determined in Mueller-Hinton medium by using an inoculum of 104 CFU per spot according to standard protocols (8) . For each compound, inductions were performed above and below the MIC with concentrations of 0.1, 1.0, 10, and 100 ,ug/ml. Log-phase cells were exposed to the inducer for 2 h, and sonic extracts of both induced and uninduced cells were dialyzed overnight at room temperature in 0.1 M potassium phosphate buffer (pH 7.0) to remove excess inducer. Enzyme activity was determined in UV assays with 100 ,uM cephalothin as the substrate (11) . All * Corresponding author.
inductions were performed in duplicate, and the results represent the averages of the two determinations. P-Lactamase activity fivefold or more greater than uninduced activity was considered significant induction. Results are not given for those concentrations of inducer which produced significant killing under conditions present in the induction assays. Those compounds giving induction ratios (induced/ uninduced enzyme activity) of <10 at all concentrations tested were considered weak inducers. Those with induction ratios of .10 only at the highest concentrations tested were considered moderate inducers, whereas those with ratios of .10 at two or more concentrations were considered strong inducers.
Cefoxitin was a strong or moderate inducer for all organisms (Table 1) . Both sulbactam and tazobactam were moderate inducers for A. caviae, M. morganii, and C. freundii. However, sulbactam was a moderate inducer for the remaining organisms, whereas tazobactam was only a weak inducer. In contrast, clavulanate was a strong inducer for M. morganii, A. caviae, and E. aerogenes and a moderate inducer for all others. All three companion P-lactams were moderate inducers for P. aeruginosa. Cefoperazone and piperacillin were both weak inducers for the remaining organisms. However, ticarcillin was also a moderate inducer for A. caviae, E. aerogenes, and S. marcescens and a strong inducer for M. morganii (Table 1) .
To extend these observations, the ability of each ,-lactamase inhibitor to induce class I enzymes was examined further in disk approximation tests (10) ,-lactamase inhibitors used in tests with Aeromonas spp. was due to the potent antibacterial activity of clavulanate against these organisms. Antagonism of ,-lactam activity through enzyme induction was detected as a flattening of the zone of inhibition produced by the P-lactam on the side adjacent to the ,-lactamase inhibitor or cefoxitin. Figure 1 illustrates a typical disk approximation test demonstrating differential antagonism by the ,B-lactamase inhibitors and cefoxitin.
VOL. 34, 1990 nized the activity of both piperacillin and ticarcillin against 53% of the strains examined and the activity of cefoperazone against 60% of the strains. In contrast to cefoxitin, clavulanate demonstrated no antagonism in tests with C. freundii and Aeromonas spp. However, in the latter case this was probably due to the strong antibacterial activity of clavulanate, since this compound was a strong inducer for A. caviae DLS4 (Table 1 ). In general, tazobactam and sulbactam did not antagonize the activity of the three P-lactam antibiotics in disk approximation tests. The sole exception was Aeromonas spp., in which both sulbactam and tazobactam antagonized the activity of piperacillin (Table 2) .
Several previous studies have examined the ability of P-lactamase inhibitors to induce class I enzymes among various members of the Enterobacteriaceae, showing that clavulanate, but not sulbactam or tazobactam, is a potent inducer of chromosomal P-lactamases (5, 6, 13) . Although the results of these studies show some quantitative differences in induction potencies for particular species, these probably reflect differences in bacterial strains and induction parameters (e.g., 2-h versus 4-h exposure to the inducer). As shown here (Table 1) , the ability of these compounds to induce chromosomal 3-lactamases is also dependent on inducer concentration and probably accounts for the absence of significant induction by clavulanate in studies using only a single, low concentration for induction (1) . The use of the disk approximation test (Table 2) to analyze a large number of strains for each species provided a more definitive assessment of the susceptibility of a particular species to induction by these compounds. It remains uncertain whether the ability of the 13-lactamase inhibitors to antagonize the in vitro activity of ,-lactam antibiotics will also occur in vivo, as has been seen with cefoxitin (2, 4) . Some have claimed that clavulanate, the most potent inducer in vitro, is unlikely to antagonize the efficacy of its companion drug in vivo since concentrations required for induction are well in excess of those achieved clinically (13) . However, it should be noted that there are many strain-to-strain variations in the susceptibility of organisms to induction by clavulanate. In addition, since ANTIMICROB. AGENTS CHEMOTHER. 
